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INTRODUCTION 
 Regulatory Affairs departments are growing within 
companies & is constantly evolving and growing and 
is the one which is least impacted during the 
Acquisition and Merger, and also during recession. 
Global harmonization in standards has led to 
consistent approach in regulatory submissions and 
hence its review. 
 Systematic formulation development acts as a back 
bone for any dossier preparation in export registration  
 There are different requirements in different countries 
for registration It is difficult for any company to 
develop product for each region Therefore; we need to 
consider majority of requirements during technical 
data submission which will help in export registration.  
 Regions, but all are national registrations in these 
countries. 
 Enormous diversity of regulatory requirements are 
there, however, harmonisation occurs as clusters e.g. 
ASEAN, Gulf 
Global Market is divided into: 
1. Regulated Market: US, EU (UK, Germany, France, 
Ireland, Sweden etc.), Japan, Canada, Australia, New 
Zealand, South Africa 
2. Semi regulated Market: (ROW Countries): 
(a) Asia (Sri Lanka, India, Bangladesh,; ASEAN: 10 
Countries group - Philippines, Vietnam Singapore, 
Malaysia, Thailand, Indonesia, Laos, Cambodia, 
Brunei Darussalam, Myanmar 
(b) African countries (Algeria, Zambia, Ethiopia, Ghana, 
Kenya, Malawi, Mozambique, Namibia, Nigeria, 
Sierra Leone, Tanzania, Zimbabwe etc) 
(c) Middle East countries (Gulf Co-operation Council 
countries i.e. Bahrain, Kuwait, Oman, Qatar, Saudi 
Arabia, UAE) 
(d) Latin America (Mexico, Brazil, Panama, Peru, 
Guatemala, Argentina, Chile, Dominican Republic)  
(e) CIS (common wealth of independent states): Russia, 
Ukraine, OFSUs (Armenia, Azerbaijan, Belarus, 
Georgia, Kazakhstan, Kirghizstan, Moldova, 
Tajikistan, Turkmenistan, Uzbekistan etc.) 
Difference from Regulated Market 
Degrees of implementation are different. Intensity of 
audits/ inspections is different and similarly penalties for 
GMP violations are different. Regulated market guidelines 
are very clear and are to be adhered to 100%  
Recent Queries raised by various ROW markets  
 Computation of batch size. 
 Chromatograms during method validation for assay 
and impurities.  
 Complete supporting data for process validation  
 Cleaning validation report  
 Reconstitution Stability (For oral suspensions):  
 Preservative content and microbial limits  
 Redispersibility and rheological properties  
 Particle size distribution  
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Registration Requirements for Rest of the World 
Administrative Documents:-  
 Certificate of Pharmaceutical Product  
 Product Permission 
 Manufacturing License 
 WHO-GMP Certificate 
 Free Sale Certificate/Export Certificate 
 Artwork (Carton, Label & Package Leaflet) 
Chemistry, Manufacturing & control documents 
API DMF Open part – Following data should be 
available in Open Part  
 Nomenclature  
 General Properties  
 Name of the Manufacturer and Site of manufacture  
 Route of Synthesis, flow diagram in brief  
 Structural Elucidation  
 Impurities  
 Specifications and Method of Analysis  
 Container Closure System  
 Stability testing – Retest period & Storage  
API Specification and Method of Analysis & COA of API 
by the Applicant 
Justification for Impurity Limits 
The following factors to be considered while fixing the 
specification limits 
• API impurity limits data (COA) 
• Check ICH requirements. 
• Check pharmacopoeial limits, if any. 
• API stability data. 
• Finished product stability data etc. 
Manufacturing Formula & Process 
 Manufacturing Formula  
 Description of manufacturing/packaging  
 Scale, Equipment by type, capacity, process 
parameters for steps (e.g. time, temp, pH), 
Environmental conditions, e.g. Relative Humidity for 
Hygroscopic materials  
 Description of In process controls/test  
 Flow Diagram- Indicate critical steps , In-process 
controls  
 Master formula  
 Batch manufacturing Record – Copy of the Master  
BMR or Completed BMR  
 Process Validation Protocols and /or reports-3 batches 
process validation reports and /or protocol is to be 
submitted. 3 Batches should be of the same size and 
should be similar to the batch size mentioned above in 
the manufacturing formula. 
 Formulation & Development is required for some 
countries like Russia, Ukraine, Algeria, Kenya, 
ASEAN etc. 
Batch Analysis  
 Results of at least one batch should be given. It should 
be preferably of the batch of which the samples will be 
submitted for registration. OR It can be of the latest 
batch, as required by the agency in the respective 
country. It should be given as certificate of analysis. 
Excipients 
 For Excipients of natural origin microbial limits 
should be specified  
 For Human or Animal origin TSE/BSE certificates 
from the manufacture should be incorporated  
 Information on Adventitious Agents should be 
provided, such as Asbestos in Talc  
 Permitted & approved Colors and Flavors should be 
used.  
 Excipients not in compendia are generally not 
recommended. Some standard mixtures comprising 
excipients in Pharmacopoeia are allowed (e.g. Opadry 
Colors). In such cases table with composition of such 
mixtures and specifications with test form the supplier 
should be provided  
 For Excipients described in compendia, copy of 
Monograph along with copies of the methods referred 
to in monograph but not appearing in monograph 
should be provided.  
 Current Pharmacopoeial monograph is always 
applicable. Details of any specifications additional to 
monograph should be provided.(e.g. particle size, 
residual solvents)  
 Excipients Certificate of Analysis tested against the 
full set of specifications. 
Finished product Specification and Method of Analysis 
 If not as per Pharmacopoeia specifications should be 
prepared as per ICH Q6A. Methods of Analysis should 
be described in details  
 If based on Pharmacopoeia additional product related 
specifications should be included as in-house 
specifications (e.g. Description, Hardness, Friability, 
Average weight, Dimensions, Identification of 
colorants, MLT). Copy of the Monograph is 
acceptable in some countries. Methods of the 
additional tests should be given. 
 If a test is based on a compendia monograph, a copy 
of the monograph + any methods referenced in the 
monograph must be submitted. 
 Details of any specifications and test methods 
additional to those in the Pharmacopoeia must be 
submitted.  
Method Validations for FP and API 
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 In few countries Validation of analytical methods is 
still not mandatory if the Pharmacopoeial method is 
followed.  
 Non-Compendial method needs to be validated if 
required by the Agency. 
Stability Data and Stability Protocol 
 Ability of pharmaceutical product to retain its property 
within specified limits throughout shelf-life 
 The stability programme includes sample size, test 
interval, storage conditions, specific methods and 
container closure system 
 Stability studies should include testing of those 
attributes of the Finished product that are susceptible 
to change during storage and are likely to influence 
quality, safety and efficacy  
 Testing should cover, the physical, chemical, 
biological and microbiological attributes, preservative 
content and functionality tests ( e.g. Nebulizer).  
 Microbial limits at release and end of shelf life. 
Dissolution limit should be same as for release.  
 API used shall preferably be of different batches. 
 Stability to be performed on each individual strength 
& container size of drug product, unless bracketing or 
matrixing is applied. 
 In conclusion Shelf life should be proposed / 
concluded including the storage condition.  
 Generally 3 batches (2 pilots, 1 smaller) data is 
required to be submitted. 
 A pilot scale batch is generally, one tenth of  a  full 
production scale or 100,000 units, whichever is larger 
 Recent modification of 30°C/70%RH condition to 
30°C/65%RH – an attempt at a single long-term global 
testing condition 
 Testing frequency and storage conditions should as per 
the ICH guidelines 
 Stability data as per Zone: {Acc.: 0, 1, 2, 3 & 6 
months; Long term: 0, 3, 6, 9, 12, 24 &36 months} 
 Local stability requirements for different countries is 
given below:- 
 
 
Attribute 
Market 
Number of 
Batches 
Stability Condition 
Long Term 
Min Duration-
ACC 
Min Duration-Long 
Term 
FWA & CA  3  Zone II  3 m  3-6 m 
ASEAN  3  Zone IV(b) 6 m 12 m 
LATAM  3  Zone IV 6 m 6 m, Vene-12 m 
Mid-East  3  Zone IV;Jordan-Z-III 6 m 12 m, SL, Jordan-24m 
CIS 3  Zone II 6 m 6 m 
 
Packing Material 
 Packing material should be suitable for storage, 
transport and compatible.  
 For Primary packing material detailed specifications 
and method of analysis including Identification for 
material of construction required. 
 For Secondary packing material specifications and 
method of analysis required 
 Printed packing material and PIL specimens and /or 
colored artworks Certificate of Analysis & Batch 
Packaging record required 
Bioequivalence 
 Compares the systemic exposure profile of a test 
product (Generic) to that of a reference product 
(Innovator Brand) 
 For the test product to be bioequivalent it should 
exhibit the same rate and extent of absorption as the 
reference product  
 Required for Tablets, Capsules and Oral Suspensions 
etc  
 It can be waived for aqueous oral solutions, Parenteral 
solutions or solutions which are locally applied and 
locally acting, for example eye drops., topical products 
inhalators or nasal spray products.  
 If Bioequivalence study is not available then 
multimedia, multipoint comparative dissolution profile 
data of the product with innovator product should be 
submitted. Data should be complied the requirement 
for F2 factor.  
Pharmacological, Toxicological data 
 Published References on Toxicological  & 
Pharmacology studies are attached in the dossier  
 Published data on clinical trials and references are 
attached in the dossier  
Registration fees- Registration fees should be paid as per 
the requirements of the Agency of importing country 
Other requirements 
 Working Standard and along with certificate of 
analysis  
 Samples of API and Excipients  
 Chromatograms, Spectra of the identification tests 
wherever applicable  
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Samples  
 As per the quality, it is mandatory to submit fresh 
finished product samples along with the dossier. The 
quantity of the sample varies as per the requirements 
of the Agency of importing country. 
SUMMARY & CONCLUSION 
 Any export market demands good quality dossier 
which can be generated through systematic 
Formulation Development. 
 The proper planning and execution of Formulation 
development will help in quality dossier & in 
answering queries from Regulatory authorities. 
 Since the world is divided in the drug approval 
procedures with technical data as described above, it is 
important especially for the generic ssmanufacturers, 
to carefully judge the market need, Development Cost, 
target regions, & regulatory requirements before the 
development of drugs. Hence it is critical to plan and 
co-ordinate all the activities for successful launch of 
product in the market on time. 
 Due to vast difference in Regulatory requirements it is 
impractical to get global marketing approval at same 
time and launch the product at once in all regions. 
Hence, one should carefully understand and define the 
clear regulatory strategy by looking at the target 
regions, different patent terms and its extension, 
various application possibilities, data requirements, 
potential timeline for marketing launch in different 
regions. This eliminates unnecessary studies, 
minimizes the delay in drug approvals and subsequent 
launch, and reduces overall cost of development. 
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